Previous 10 | Next 10 |
Acer Therapeutics Inc. (NASDAQ: ACER) is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, according to the company’s website (see here: www.ac...
Gainers: Renren (NYSE: RENN ) +66% . More news on: Renren Inc., SemiLEDs Corporation, Cheetah Mobile Inc., Stocks on the move, , Read more ...
Pyxus International (NYSE: PYX ) -26% . More news on: Pyxus International, Inc., Nano Dimension Ltd., Medigus Ltd., Stocks on the move, , Read more ...
Acer Therapeutics (NASDAQ: ACER ): Q1 GAAP EPS of -$0.49 misses by $0.09 . More news on: Acer Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEWTON, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported fina...
CymaBay Therapeutics (NASDAQ: CBAY ) +147% on upgrades and Q1 results . More news on: CymaBay Therapeutics, Inc., Novavax, Inc., NanoViricides, Inc., News on the U.S. economy Read more ...
Acer Therapeutics (NASDAQ: ACER ) inks an agreement with NIH's National Center for Advancing Translational Sciences to develop antiviral emetine hydrochloride for the potential treatment of COVID-19 administered via subcutaneous injection. More news on: Acer Therapeutics Inc., Healthcare...
Targeting Q3 2020 initiation of an adaptive Phase 2/3 trial evaluating emetine in high-risk COVID-19 outpatients, following IND submission and clearance Acer to host conference call and webcast on Monday, May 11 at 5:30 pm Eastern Time NEWTON, Mass., May 11, 2020 (GLOBE NEWSWIRE) -...
NEWTON, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced i...
On March 18th Acer Therapeutics ( ACER ) announced that the FDA's Office of New Drugs (OND) denied Acer's appeal of the Complete Response Letter ("CRL") received last June in relation to Acer's New Drug Application (NDA) for EDSIVO™ for the treatment of patients with vascular Ehlers-D...
News, Short Squeeze, Breakout and More Instantly...
Acer Therapeutics Inc. Company Name:
ACER Stock Symbol:
NASDAQ Market:
Acer Therapeutics Inc. Website:
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Acer Therapeutics Inc. (ACER) is expected to report $-0.13 for Q3 2023